問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

Division of Cardiovascular Diseases

更新時間:2023-09-19

傅家保
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

47Cases

2010-05-01 - 2011-04-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-12-01 - 2012-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-07-01 - 2012-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2025-07-01 - 2028-12-31

Phase III

Active
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
  • Condition/Disease

    -Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8 -Achieving normalization of the Renin Angiotensin Aldosterone system (RAAS) at week 8

  • Test Drug

    Baxdrostat

Participate Sites
6Sites

Recruiting6Sites

2025-07-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-01-01 - 2025-06-30

Phase III

Active
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 OA investigational vaccine

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2023-02-01 - 2025-12-31

Phase III

Completed
An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)
  • Condition/Disease

    Severe Hypertriglyceridemia

  • Test Drug

    Olezarsen (ISIS 678354)

Participate Sites
7Sites

Recruiting7Sites

2024-08-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5